OCA
RVMD icon

Octagon Capital Advisors’s Revolution Medicines RVMD Stock Holding History

Octagon Capital Advisors’s Portfolio RVMD Stock Details RVMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-126,136
Closed -$4M – 34
2021
Q2 		$4M Hold
126,136
– – 0.83% 30
2021
Q1 		$5.79M Hold
126,136
– – 2.18% 20
2020
Q4 		$4.99M Buy
+126,136
New +$4.99M 1.73% 19

Other funds holding RVMD

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
CG
Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Octagon Capital Advisors's RVMD Position: Q3 2021 in Review

Octagon Capital Advisors sold out of Revolution Medicines (RVMD) in Q3 2021, closing a stake of 126,136 shares — an estimated $4M sold.

Octagon Capital Advisors first reported a position in RVMD in Q4 2020 and held it in 3 quarters. The position peaked at $5.79M in Q1 2021. 114 funds tracked by Wall St. Rank hold RVMD as of Q3 2021.

  • Octagon Capital Advisors reported no remaining Revolution Medicines position as of Q3 2021 after selling out during the quarter.
  • Octagon Capital Advisors sold 126,136 Revolution Medicines shares in Q3 2021, an estimated $4M.
  • Octagon Capital Advisors first reported a position in Revolution Medicines in Q4 2020 and held it in 3 quarters.
  • Octagon Capital Advisors's Revolution Medicines position peaked at $5.79M in Q1 2021.
  • 114 funds tracked by Wall St. Rank held Revolution Medicines as of Q3 2021.

Based on Octagon Capital Advisors's 13F filing for Q3 2021, filed 15 Nov 2021.